Skip to main content

Clinical Trials Using Tafasitamab

Review the clinical trials studying tafasitamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
Status: Active
Location: 104 locations
Epcoritamab with Lenalidomide and Tafasitamab for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The ECLAT Trial
Status: Active
Location: 7 locations
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 5 locations
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Status: Active
Location: 3 locations
Tafasitamab and Zanubrutinib for the Treatment of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Status: Active
Location: 3 locations
Tafasitamab and Lenalidomide as First Salvage Therapy for Relapsed or Refractory Large B-Cell Lymphoma after Axicabtagene Ciloleucel
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tafasitamab in Combination with Lenalidomide and Rituximab for the Treatment of Follicular Lymphoma and Marginal Zone Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for the Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Lenalidomide with Tafasitamab for the Treatment of Relapsed Central Nervous System Diffuse Large B-cell Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
AD-PluReceptor NK Cells plus Tafasitamab-Cxix and Lymphodepleting Chemotherapy for the Treatment of Patients with Systemic Sclerosis or System Lupus Erythematosus
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tafasitamab, Retifanlimab, and Rituximab in Combination with Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients with Chronic Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Zanubrutinib and Tafasitamab for the Treatment of Relapsed or Untreated Mantle Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida